The Pharmaceutical Market: Saudi Arabia
OVERVIEW OF THE PHARMACEUTICAL
MARKET IN SAUDI ARABIA
Saudi Arabia\' s transition to an
increasingly privatised and comprehensive healthcare system will
drive the demand for both patented and generic drugs . The country is
investing heavily in healthcare infrastructure and we expect this
will be borne out in double-digit growth forecasts across our three
headline indicators.
Headline Expenditure Projections
- Pharmaceuticals: SAR16.70bn (US$4.46bn) in 2011 to SAR18.95bn (US$5.06bn) in 2012; +13.5% in local currency and US dollar terms. Forecastbroadly unchanged from Q3 12.
- Healthcare: SAR78.63bn (US$21.00bn) in 2011 to SAR91.20bn (US$24.35bn) in 2012; +16.0% in local currency and US dollar terms. Forecast broadly unchanged from Q3 12.
- Medicaldevices: SAR5.54bn (US$1.48bn) in 2011 to SAR6.53bn (US$1.74bn) in 2012; +17.8% in local currency and US dollar terms. Forecastunchanged from Q3 12.
To
Browse a Full Report with TOC @
http://www.researchmoz.us/the-pharmaceutical-market-saudi-arabia-report.html
Risk/Reward
Rating
Saudi
Arabia\'s composite score remained steady in Q4 12 at 55.6. This
places the country to firth place out of the 30 markets in the
region. Its score is propped up by the country\'s wealth and a
sizeable population (exceeding 28mn in 2011). Furthermore, its
forecast growth rate is high due to favourable public and private
healthcare investments. The government is also in the process of
creating more public-private health partnerships and encouraging
private health insurance uptake, which should provide momentum for
drug sales.
Competitive
Landscape
The
competitive landscape section provides comparative company analyses
and rankings by US$ sales and % share of total sales - for the total
pharmaceutical sector, as well as the OTC, generics, and distribution
sub-sectors.
Table
of Contents
Rewards14
Risks14
Saudi
Arabia - Market Summary16
Regulatory
Regime18
Regulatory
Developments19
Regional
Regulatory Developments20
Free
Trade Agreements21
Intellectual
Property Regime21
IP
Deficiencies23
Counterfeit
Drugs25
OTC
Drug Market25
Pricing
Regime25
Reimbursement
Regime26
Pricing
System Reform26
Tendering
Procedures27
Industry
Trends And Developments29
Epidemiology29
Public
Health Developments30
For More Information Kindly Contact:
ResearchMoz
Mr.
Nachiket Ghumare,
Tel:
866-997-4948
(Us-Canada
Toll Free)
Tel:
+1-518-621-2074
Website:
http://www.researchmoz.us
Comments
Post a Comment